New method to target drug-resistant breast cancers using enzyme-stimulated peptides
Official title: New approach based on enzyme stimulating of peptides for targeting drug resistance breast cancers
Funded at University of North Texas · NIH-11100366 · Data updated 2026-11-12
This study is exploring new treatments for triple-negative breast cancer by using specially designed molecules to target a specific enzyme, aiming to stop the cancer cells from growing and help patients who often struggle with standard therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Texas NIH-funded |
| Lab location | 1 site (Denton, United States) |
| Project start | August 17, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $41,666 |
| NIH project number | 3R16GM150848-02S1 |
| Project ID | NIH-11100366 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple-negative breast cancer or other forms of drug-resistant breast cancer.
✕Less likely to help
Patients with hormone receptor-positive breast cancers may not benefit from this research.
What this research studies
This research focuses on developing innovative therapies for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer that lacks common hormone receptors. The approach involves using specially designed peptides that interact with a specific enzyme, Eyes Absent (EYA), to inhibit the growth of TNBC cells. By leveraging the unique biochemical properties of EYA, the study aims to create nanostructures that can induce cell death in TNBC tumors. This method represents a shift from traditional treatments that often fail in TNBC cases.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with drug-resistant breast cancers.
How similar studies have gone: While the approach of using enzyme-stimulated peptides is innovative, similar strategies targeting cancer cell growth have shown promise in preliminary studies.
Where this research is happening
-
University of North Texas
Denton, United States Active
Researchers
- Principal investigator: Habibi, Neda — University of North Texas
- Study coordinator: Habibi, Neda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.